Qsymia Dosing and Administration

Introduction to Qsymia

The American College of Cardiology and other guideline societies recommend Qsymia, a combination medication of phentermine and topiramate, for chronic weight management, available in four capsule dose forms: 3.75/23 mg, 7.5/46 mg, 11.25/69 mg, and 15/92 mg, designed to be taken once daily in the morning as part of a gradual dose escalation regimen 1, 2

Qsymia is available exclusively as extended-release (ER) capsules in four different strengths, including 3.75 mg phentermine/23 mg topiramate, 7.5 mg phentermine/46 mg topiramate, 11.25 mg phentermine/69 mg topiramate, and 15 mg phentermine/92 mg topiramate 1, 3
The medication should be taken once daily in the morning, following a specific dose escalation schedule, with an initial dose of 3.75/23 mg daily for 14 days, then increased to 7.5/46 mg daily, and potentially further titrated to 11.25/69 mg daily and 15/92 mg daily (maximum dose) 2, 3

The recommended dose titration schedule involves an initial dose of 3.75/23 mg daily for 14 days, then increased to 7.5/46 mg daily, with evaluation of effectiveness at 12 weeks and consideration of further titration if needed, with the goal of achieving at least 3% weight loss at the 7.5/46 mg daily dose and at least 5% weight loss at the maximum 15/92 mg daily dose 1, 2
Treatment should be discontinued if 5% weight loss is not achieved after 12 weeks at the maximum 15/92 mg daily dose, as recommended by the American Heart Association and other guideline societies 2, 3

Qsymia was the first combination medication for chronic weight management approved by the FDA in 2012, with a fixed-dose combination that targets different mechanisms simultaneously for an additive effect on weight loss, addressing the complex nature of obesity, as noted by the National Institutes of Health and other health organizations 1, 2
In clinical trials, Qsymia demonstrated significant weight loss compared to placebo, with a 7.5/46 mg daily dose resulting in 7.8% weight loss at 1 year and a 15/92 mg daily dose resulting in 9.8% weight loss at 1 year, as reported by the American Diabetes Association and other medical societies 4, 5
Common side effects of Qsymia include paresthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth, as noted by the FDA and other regulatory agencies 4, 6
Qsymia is contraindicated during pregnancy due to the risk of fetal malformations (particularly cleft lip/palate) associated with topiramate, as warned by the FDA and other health organizations 7, 8

Gradual dose escalation helps minimize risks and adverse events, and Qsymia should be taken once daily in the morning, not in divided doses, as recommended by the American College of Cardiology and other medical societies 2
Regular monitoring is recommended at least monthly for the first 3 months and then at least every 3 months thereafter, with women of childbearing potential required to use effective contraception while taking Qsymia due to teratogenic risks, as advised by the FDA and other health organizations 4, 8